UK markets closed

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4200+0.0200 (+1.43%)
As of 01:05PM EDT. Market open.
Full screen
Loading interactive chart…
  • Business Wire

    Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

    GAINESVILLE, Fla., March 18, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

  • Business Wire

    Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

    GAINESVILLE, Fla., March 14, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, "Methods for Treating Alzheimer’s Disease," with claims that cover the use of Trappsol® Cyclo™ for th

  • GlobeNewswire

    Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

    Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024. “During fiscal 2024, we will continue to focus on advancing our existing portfolio